Erratum: Lead identification to clinical candidate selection: Drugs for chagas disease (Journal of Biomolecular Screening (2015) 20 (101-111) DOI: 10.1177/1087057114553103);Lead identification to clinical candidate selection: Drugs for chagas disease

Journal of Biomolecular Screening

Volumn 20, Issue 1, 2015, Pages 101-111

  Jeffrey Neitz, R ^a   Chen, Steven ^a   Supek, Frantisek ^b   Yeh, Vince ^b   Kellar, Danielle ^c,d,e   Gut, Jiri ^c,d   Bryant, Clifford ^a   Gallardo Godoy, Alejandra ^a   Molteni, Valentina ^b   Roach, Steven L ^b,f   Chatterjee, Arnab K ^b,g   Robertson, Stephanie ^a   Renslo, Adam R ^a   Arkin, Michelle ^a   Glynne, Richard ^b   McKerrow, James ^c,d,h   Siqueira Neto, Jair L ^c,d,h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c University of California at San Francisco   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e FIVE PRIME THERAPEUTICS INC   (United States)

^f DART NEUROSCIENCE LLC   (United States)

^g California Institute for Biomedical Research   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

cell based assays; Chagas disease; drug discovery; high content screening; high throughput screening

Indexed keywords

ANTIPARASITIC AGENT; BETA GALACTOSIDASE; ERGOSTEROL; XANTHINE DERIVATIVE; ANTITRYPANOSOMAL AGENT; MOLECULAR LIBRARY; XANTHINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHAGAS DISEASE; COLORIMETRY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG SOLUBILITY; HIGH THROUGHPUT SCREENING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PUBLIC-PRIVATE PARTNERSHIP; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; UNITED STATES; ANIMAL; CELL LINE; CHEMISTRY; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; MOLECULAR LIBRARY; NEGLECTED DISEASES; PROCEDURES;

TRYPANOSOMA CRUZI;

ANIMALS; CELL LINE; CHAGAS DISEASE; COLORIMETRY; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; NEGLECTED DISEASES; SMALL MOLECULE LIBRARIES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; XANTHINE;

EID: 84920095260     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115593092     Document Type: Erratum

References (35)

1. Chagas C. Nova trypanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., sp., ajente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz. 1909 ; 1: 159-218
2. Rassi A., Rassi A., Marin-Neto J. A.. Chagas Disease. Lancet. 2010 ; 375: 1388-1402
3. Coura J. R., Vinas P. A.. Chagas Disease: A New Worldwide Challenge. Nature. 2010 ; 465: S6 - S7
4. WHO Fact Sheet 340: Chagas Disease (American Trypano-somiasis). http://www.who.int/mediacentre/factsheets/fs340/en/
5. Bern C., Montgomery S. P.. An Estimate of the Burden of Chagas Disease in the United States. Clin. Infect. Dis. 2009 ; 49: e52 - e54
6. Hotez P. J., Dumonteil E., Woc-Colburn L., et al. Chagas Disease: "The New HIV/AIDS of the Americas.". PLoS Negl. Trop. Dis. 2012 ; 6: e1498
7. Carrilero B., Murcia L., Martinez-Lage L., et al. Side Effects of Benznidazole Treatment in a Cohort of Patients with Chagas Disease in Non-Endemic Country. Rev. Esp. Quimioter. 2011 ; 24: 123-126
8. Castro J. A., Diaz de Toranzo E. G.. Toxic Effects of Nifurtimox and Benznidazole, Two Drugs Used against American Trypanosomiasis (Chagas' Disease). Biomed. Environ. Sci. 1988 ; 1: 19-33
9. Hasslocher-Moreno A. M., do Brasil P. E., de Sousa A. S., et al. Safety of Benznidazole Use in the Treatment of Chronic Chagas' Disease. J. Antimicrob. Chemother. 2012 ; 67: 1261-1266
10. Viotti R., Vigliano C., Lococo B., et al. Side Effects of Benznidazole as Treatment in Chronic Chagas Disease: Fears and Realities. Expert Rev. Anti Infect. Ther. 2009 ; 7: 157-163
11. Molina I., Gomez i, Prat J., Salvador F., et al. Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease. N. Engl. J. Med. 2014 ; 370: 1899-1908
12. Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy. http://www.dndi.org/media-centre/press-releases/1700-e1224.html
13. Rottingen J. A., Regmi S., Eide M., et al. Mapping of Available Health Research and Development Data: What's There, What's Missing, and What Role Is There for a Global Observatory?. Lancet. 2013 ; 382: 1286-1307
14. Nwaka S.. Drug Discovery and Beyond: The Role of Public-Private Partnerships in Improving Access to New Malaria Medicines 2005. Trans. R. Soc. Trop. Med. Hyg 99.: S20 - S29
15. Product Development Partnership Model. http://www.mmv.org/partnering/product-development-partnership-model
16. Kettler H. E., Marjanovic S.. Engaging Biotechnology Companies in the Development of Innovative Solutions for Diseases of Poverty. Nat. Rev. Drug Discov. 2004 ; 3: 171-176
17. Chatelain E., Ioset J. R.. Drug Discovery and Development for Neglected Diseases: The DNDi Model. Drug Des. Dev. Ther. 2011 ; 5: 175-181
18. Eisai Enters Global Agreement with Broad Institute to Develop New Drugs for Neglected Diseases and Tuberculosis. http://www.eisai.com/news/news201364.html
19. Neal R. A., van Bueren J.. Comparative Studies of Drug Susceptibility of Five Strains of Trypanosoma cruzi In Vivo and In Vitro. Trans. R. Soc. Trop. Med. Hyg. 1988 ; 82: 709-714
20. Moraes C. B., Giardini M. A., Kim H., et al. Nitroheterocyclic Compounds Are More Efficacious Than CYP51 Inhibitors against Trypanosoma cruzi: Implications for Chagas Disease Drug Discovery and Development. Sci. Rep. 2014 ; 4: 4703
21. SchwiebertE.StreiffJ.DixonJ.. Small Molecule Bicyclic and Tricyclic CFTR Correctors. USPTO (Patent), WO2014081821 A2, 2013.
22. Engel J. C., Doyle P. S., Dvorak J. A.. Trypanosoma cruzi: Biological Characterization of Clones Derived from Chronic Chagasic Patients: II. Quantitative Analysis of the Intracellular Cycle. J. Protozool. 1985 ; 32: 80-83
23. Canavaci A. M., Bustamante J. M., Padilla A. M., et al. In Vitro and In Vivo High-Throughput Assays for the Testing of anti-Trypanosoma cruzi Compounds. PLoS Negl. Trop. Dis. 2010 ; 4: e740
24. Buckner F. S., Verlinde C. L., La Flamme A. C., et al. Efficient Technique for Screening Drugs for Activity against Trypanosoma cruzi Using Parasites Expressing Beta-Galactosidase. Antimicrob. Agents Chemother. 1996 ; 40: 2592-2597
25. Buckner F. S., Griffin J. H., Wilson A. J., et al. Potent Anti-Trypanosoma cruzi Activities of Oxidosqualene Cyclase Inhibitors. Antimicrob. Agents Chemother. 2001 ; 45: 1210-1215
26. Li C., Liu B., Chang J., et al. A Modern In Vivo Pharmacokinetic Paradigm: Combining Snapshot, Rapid and Full PK Approaches to Optimize and Expedite Early Drug Discovery. Drug Discov. Today. 2013 ; 18: 71-78
27. Skolnik S., Lin X., Wang J., et al. Towards Prediction of In Vivo Intestinal Absorption Using a 96-Well Caco-2 Assay. J. Pharm. Sci. 2010 ; 99: 3246-3265
28. Di L., Kerns E. H., Hong Y., et al. Development and Application of High Throughput Plasma Stability Assay for Drug Discovery. Int. J. Pharm. 2005 ; 297: 110-119
29. Engel J. C., Ang K. K., Chen S., et al. Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease. Antimicrob. Agents Chemother. 2010 ; 54: 3326-3334
30. Keenan M., Chaplin J. H., Alexander P. W., et al. Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease. J. Med. Chem. 2013 ; 56: 10158-10170
31. Hamilton-Miller J. M., Shah S.. Effect of Antibiotic Concentration on the Killing of Staphylococcus aureus and Enterococcus faecalis: Comparison of the Novel Penem, Men 10700, with Other Beta-Lactam Antibiotics. J. Antimicrob. Chemother. 1999 ; 44: 418-420
32. Stevens D. L., Gibbons A. E., Bergstrom R., et al. The Eagle Effect Revisited: Efficacy of Clindamycin, Erythromycin, and Penicillin in the Treatment of Streptococcal Myositis. J. Infect. Dis. 1988 ; 158: 23-28
33. Berens R. L., Marr J. J., LaFon S. W., et al. Purine Metabolism in Trypanosoma cruzi. Mol. Biochem. Parasitol. 1981 ; 3: 187-196
34. Kanehisa M., Goto S., Sato Y., et al. Data, Information, Knowledge and Principle: Back to Metabolism in KEGG. Nucleic Acids Res. 2014 ; 42: D199 - D205
35. Purine Metabolism - Trypanosoma cruzi (KEGG PATHWAY). http://www.genome.jp/kegg-bin/show-pathway?tcr00230+506697.20